K562 (Chronic myeloid leukemia, Prof. Ufuk Gündüz Laboratory, Turkey) and CCRF-CEM (Acute lymphoid leukemia, DSMZ, Germany) cells were cultivated in 1X RPMI1640 medium (Medsantek/dist. Gibco, TR) enriched with 10% fetal bovine serum (Interlab/dist. BI, TR), 1% nonessential aminoacids (Interlab/dist. Sigma Aldrich, TR), and 1% penicillin/streptomycin (Interlab/dist. Sigma Aldrich, TR) in T25 cell culture flasks. Subculturing and drug resistance development procedures were presented in our previous work25. The same cells were used in this study after 4 passages. Based on IC50 analyses, K562 cells were classified as high-level laboratory drug resistant models with approximately 60-fold resistance to imatinib as compared to wild type K562 cells, while CCRF-CEM cells were categorized as a clinically relevant model with approximately fourfold resistance to doxorubicin as compared to their wild type progenies25,26.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。